Literature DB >> 4472416

Treatment of Paget's disease of bone with synthetic salmon calcitonin.

J A Kanis, D B Horn, R D Scott, J A Strong.   

Abstract

Thirteen patients with painful Paget's disease of bone were treated as outpatients with low doses of synthetic salmon calcitonin 22.5-50 mug three times weekly. Treatment produced full remission of pain in a mean time of 5.5 weeks and a mean depression of serum alkaline phosphatase activity of 33%.The interval before symptomatic relief could not be predicted from the variables studied. The ultimate fall in serum alkaline phosphatase activity, however, could be predicted from the initial levels and from the early rate of decrease (P < 0.001). Biochemical resistance to treatment, which occurred in three cases, could be related to the dose and duration of treatment.Prolonged remissions of pain may occur which are not related to biochemical remission, to the dose of calcitonin, or to the duration of treatment. The side effects attributable to salmon calcitonin were transient nausea (in nine patients), transient flushing (in four), diarrhoea (in two), and rash (in one) though in only one patient did treatment have to be withdrawn prematurely because of these effects.

Entities:  

Mesh:

Substances:

Year:  1974        PMID: 4472416      PMCID: PMC1611841          DOI: 10.1136/bmj.3.5933.727

Source DB:  PubMed          Journal:  Br Med J        ISSN: 0007-1447


  18 in total

1.  Effect of calcitonin and vitamin D on radiological changes in Paget's disease.

Authors:  G M Palmieri; B Eaton; D E Beahm; W Joel; P Grozea; J Hawrylke
Journal:  Lancet       Date:  1972-12-09       Impact factor: 79.321

2.  Radiological regression in Paget's disease treated by human calcitonin.

Authors:  N J Woodhouse; G F Joplin; I MacIntyre; F H Doyle
Journal:  Lancet       Date:  1972-11-11       Impact factor: 79.321

3.  Human calcitonin in the treatment of Paget's bone disease.

Authors:  N J Woodhouse; P Bordier; M Fisher; G F Joplin; M Reiner; D N Kalu; G V Foster; I MacIntyre
Journal:  Lancet       Date:  1971-06-05       Impact factor: 79.321

4.  Effect of actinomycin D on Paget's disease of bone.

Authors:  J J Fennelly; J F Groarke
Journal:  Br Med J       Date:  1971-02-20

5.  [Synthesis of salmon calcitonin, a high activity hypocalcemic hormone].

Authors:  S Guttmann; J Pless; R L Huguenin; E Sandrin; H Bossert; K Zehnder
Journal:  Helv Chim Acta       Date:  1969       Impact factor: 2.164

6.  Effects of prolonged thyrocalcitonin administration on Paget's disease of bone.

Authors:  J G Haddad; S J Birge; L V Avioli
Journal:  N Engl J Med       Date:  1970-09-10       Impact factor: 91.245

7.  Calcitonin resistance: clinical and immunologic studies in subjects with Paget's disease of bone treated with porcine and salmon calcitonins.

Authors:  J G Haddad; J G Caldwell
Journal:  J Clin Invest       Date:  1972-12       Impact factor: 14.808

8.  The clinical and metabolic effects of porcine calcitonin on Paget's disease of bone.

Authors:  F Shai; R K Baker; S Wallach
Journal:  J Clin Invest       Date:  1971-09       Impact factor: 14.808

9.  Treatment of Paget's disease of bone with mithramycin.

Authors:  J R Condon; S B Reith; J R Nassim; F J Millard; A Hilb; E M Stainthorpe
Journal:  Br Med J       Date:  1971-02-20

10.  Glucagon in the treatment of Paget's disease of bone.

Authors:  J R Condon
Journal:  Br Med J       Date:  1971-12-18
View more
  14 in total

1.  Medical staff conference. Paget disease of bone.

Authors: 
Journal:  West J Med       Date:  1978-09

Review 2.  Treatment of patients with Paget's disease of bone.

Authors:  C Roux; M Dougados
Journal:  Drugs       Date:  1999-11       Impact factor: 9.546

Review 3.  Salmon calcitonin: a review of current and future therapeutic indications.

Authors:  C H Chesnut; M Azria; S Silverman; M Engelhardt; M Olson; L Mindeholm
Journal:  Osteoporos Int       Date:  2007-12-11       Impact factor: 4.507

4.  The possible role of calcitonin deficiency in the development of bone disease due to chronic renal failure.

Authors:  J A Kanis; M Earnshaw; G Heynen; R G Russell; C G Woods
Journal:  Calcif Tissue Res       Date:  1977-05

5.  Paget's disease of bone.

Authors: 
Journal:  Br Med J       Date:  1977-06-04

6.  The effect of rectal and nasal administration of salmon calcitonin in normal subjects.

Authors:  T Buclin; J P Randin; A F Jacquet; M Azria; M Attinger; F Gomez; P Burckhardt
Journal:  Calcif Tissue Int       Date:  1987-11       Impact factor: 4.333

7.  Effect of intranasal salmon calcitonin therapy on bone mass and bone turnover in early postmenopausal women: a dose-response study.

Authors:  K Overgaard
Journal:  Calcif Tissue Int       Date:  1994-08       Impact factor: 4.333

Review 8.  Paget's disease of bone.

Authors:  D J Hosking
Journal:  Br Med J (Clin Res Ed)       Date:  1981-09-12

9.  Paget's disease of bone.

Authors:  E S Siris; T P Jacobs; R E Canfield
Journal:  Bull N Y Acad Med       Date:  1980-04

10.  Management of fissure fractures in Paget's disease.

Authors:  J F Redden; J Dixon; W Vennart; D J Hosking
Journal:  Int Orthop       Date:  1981       Impact factor: 3.075

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.